anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: When hemodialysis arteriovenous accesses fail, autogenous options are often limited. Non-autogenous conduit choices include bovine carotid artery xenografts (BCAG) and expanded polytetrafluoroethylene (PTFE), yet their comparative effectiveness in hemodialysis access revision remains largely unknown.
METHODS: A cohort study was performed from a prospectively collected institutional database from August 2010 to July 2021. All patients undergoing an arteriovenous access revision with either BCAG or PTFE were followed for up to 3 years from their index access revision. Revision was defined as graft placement to address a specific problem of an existing arteriovenous access while maintaining one or more of the key components of the original access (e.g. inflow, outflow, and cannulation zone). Outcomes were measured starting at the date of the index revision procedure. The primary outcome was loss of secondary patency at 3 years. Secondary outcomes included loss of post-intervention primary patency, rates of recurrent interventions, and 30-day complications. Pooled logistic regression was used to estimate inverse probability weighted marginal structural models for the time-to-event outcomes of interest.
RESULTS: A total of 159 patients were included in the study, and 58% received access revision with BCAG. Common indications for revision included worn out cannulation zones (32%), thrombosis (18%), outflow augmentation (16%), and inflow augmentation (13%). Estimated risk of secondary patency loss at 3 years was lower in the BCAG group (8.6%, 3.9-15.1) compared to the PTFE group (24.8%, 12.4-38.7). Patients receiving BCAG experienced a 60% decreased relative risk of secondary patency loss at 3 years (risk ratio 0.40, 0.14-0.86). Recurrent interventions occurred at similar rates in the BCAG and PTFE groups, with 1.86 (1.31-2.43) and 1.60 (1.07-2.14) interventions at 1 year, respectively (hazard ratio 1.22, 0.74-1.96).
CONCLUSIONS: Under the conditions of this contemporary cohort study, use of BCAG in upper extremity hemodialysis access revision decreased access abandonment when compared to PTFE.
Patients perform a rehabilitation treatment of 15 or 20 sessions with lokomat + 15 or 20 sessions of physiotherapy in 3 or 4 weeks as defined by the clinician. During two or three sessions they wear a wearable device Empatica E4 that measure their electrocardiographic (ECG) activity and electrodermal activity (EDA). They also have a baseline acquisition of these signals in their room at hospital.
Group C participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
Participants in the Experimental Group (EG) were asked to attend an orientation reviewing the study. Then they were instructed to complete 4 activities on the dvSS ® that modeled suturing techniques in minimally invasive robotics-assisted surgery. EG participants repeated these 4 activities over a period of 2 weeks until they reached proficiency (91%) in all 4 activities. 4. Participants were asked to return where they were filmed and timed completing a suturing activity on the porcine model.
BACKGROUND: Neglected tropical diseases (NTDs) affect over 1.5 billion people worldwide, primarily impoverished populations in low- and middle-income countries. Skin NTDs, a significant subgroup, manifest primarily as skin lesions and require extensive diagnosis and treatment resources, including trained personnel and financial backing. The World Health Organization has introduced the SkinNTDs app, a mobile health tool designed to train and be used as a decision support tool for frontline health care workers. As most digital health guidelines prioritize the thorough evaluation of mobile health interventions, it is essential to conduct a rigorous and validated assessment of this app.
OBJECTIVE: This study aims to assess the usability and user experience of World Health Organization SkinNTDs app (version 3) as a capacity-building tool and decision-support tool for frontline health care workers.
METHODS: A cross-sectional study was conducted in Ghana and Kenya. Frontline health care workers dealing with skin NTDs were recruited through snowball sampling. They used the SkinNTDs app for at least 5 days before completing a web-based survey containing demographic variables and the user version of the Mobile Application Rating Scale (uMARS), a validated scale for assessing health apps. A smaller group of participants took part in semistructured interviews and one focus group. Quantitative data were analyzed using SPSS with a 95% CI and P≤.05 for statistical significance and qualitative data using ATLAS.ti to identify attributes, cluster themes, and code various dimensions that were explored.
RESULTS: Overall, 60 participants participated in the quantitative phase and 17 in the qualitative phase. The SkinNTDs app scored highly on the uMARS questionnaire, with an app quality mean score of 4.02 (SD 0.47) of 5, a subjective quality score of 3.82 (SD 0.61) of 5, and a perceived impact of 4.47 (SD 0.56) of 5. There was no significant association between the app quality mean score and any of the categorical variables examined, according to Pearson correlation analysis; app quality mean score vs age (P=.37), sex (P=.70), type of health worker (P=.35), country (P=.94), work context (P=.17), frequency of dealing with skin NTDs (P=.09), and dermatology experience (P=.63). Qualitative results echoed the quantitative outcomes, highlighting the ease of use, the offline functionality, and the potential utility for frontline health care workers in remote and resource-constrained settings. Areas for improvement were identified, such as enhancing the signs and symptoms section.
CONCLUSIONS: The SkinNTDs app demonstrates notable usability and user-friendliness. The results indicate that the app could play a crucial role in improving capacity building of frontline health care workers dealing with skin NTDs. It could be improved in the future by including new features such as epidemiological context and direct contact with experts. The possibility of using the app as a diagnostic tool should be considered.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.2196/39393.
PCT No. PCT/EP93/01774 Sec. 371 Date Feb. 21, 1995 Sec. 102(e) Date Feb. 21, 1995 PCT Filed Jul. 3, 1993 PCT Pub. No. WO94/01436 PCT Pub. Date Jan. 20, 1994The invention provides compounds of formula I    <IMAGE>  I  and pharmaceutically acceptable salts thereof; wherein R50 is hydrogen or C1-4 alkyl, A51 is oxygen, sulphur or a group of the formula -NR52- wherein R52 is hydrogen or C1-4 alkyl; A50 comprises i) a mono or bicyclic aromatic ring optionally containing one or more nitrogen, oxygen or sulphur atoms, ii) a cycloalkendiyl group, or iii) an acyclic bridging group having a chain of one, two or three atoms between the cyclobutenedione group and X50, said chain being a chain of one or two carbon atoms or a chain of one carbon atom and one or more nitrogen, oxygen or sulphur atoms or iv) a bond; X50 is either a bond or a spacer group providing a chain between A50 and B50 of one or two atoms length; B50 is a mono or bicyclic aromatic-ring optionally containing one or more nitrogen, oxygen or sulphur atoms; r is an integer from 1 to 6; and Het is a ring system optionally containing one or more nitrogen, oxygen or sulphur atoms or is a phosphonate, phosphinate or amine derivative (wherein each of A50, X50, B50 and Her are optionally substituted). The compounds have angiotensin II antagonist activity and are useful in the treatment of cardiovascular disorders such as hypertension.
Have the invention discloses one kind and treating infectious bronchitis of chicken eupatorium lindleynun var. trifoliolatum granule, the eupatorium lindleynun var. trifoliolatum granule major ingredient includes by weight：35~55 parts of eupatorium lindleynun var. trifoliolatum, 20~40 parts of radix scutellariae, 15~35 parts of Fructus Forsythiae, 15~30 parts of campanulaceae, 10~20 parts of Radix Glycyrrhizae；The auxiliary material of eupatorium lindleynun var. trifoliolatum granule includes 3~6 parts of corrigent, 5~10 parts of sweetener, 20~30 parts of forming agent by weight；There should be treatment infectious bronchitis of chicken eupatorium lindleynun var. trifoliolatum granule, eupatorium lindleynun var. trifoliolatum thick paste is fabricated to by particle using forming agent, the bitter taste in eupatorium lindleynun var. trifoliolatum is set to include, it is allowed to not show bitter taste under the premise of not losing ingredient and not affecting the treatment, significantly improve the mouthfeel of preparation, not only it had avoided with a large amount of sucrose flavor adjustments, but also has reduced preparation loading amount；The present invention's has treatment infectious bronchitis of chicken with eupatorium lindleynun var. trifoliolatum granule compared with syrup, and administering mode is the same, is oral medication, and good absorbing is proved effective fast, and curative for effect consistent, toxic side effect is small, highly practical, use easy to spread.
Abemaciclib will be given as a single oral agent A sample size of 10 subjects is determined to be minimally sufficient for these pilot study objectives. The starting dose will be 200 mg twice daily. Dosing will continue daily for 28 days, this being one cycle. There will be no protocol scheduled hiatus and daily dosing will be continuous unless there is unacceptable toxicity, disease progression, or death.
Olive leaf polyphenol concentrate (OLPC) extraction OLPC was prepared from olive leaves as follows (Zaslave et al, 2005) : The leaves were randomly picked from the Barnea cultivar in the Jezreel Valley region of Israel and immediately freeze-dried on dry ice. After the leaves were thoroughly rinsed with sterile distilled water to remove dust, insecticides, and contaminating material, the leaves were ground and successively Soxhlet extracted with hexane for 3 h and 80% aqueous ethanol for 6 h. The alcoholic extract was concentrated under reduced pressure at 25 °C, and reconstituted with 30% ethanol in water.
PURPOSE: To obtain a cosmetic capable of preventing the aging of the skin, making the skin beautiful, improving the texture, color, gloss, etc., of the skin and further protecting the skin from microorganisms. CONSTITUTION: This cosmetic is obtained by compounding a cosmetic with the sea water obtained from the Dead Sea or the salt obtained from the water. The composition of the salt is: MgCl2 , 30.0-34.0%; KCl, 22.0-28.0%; NaCl, 12.0-18.0%; CaCl2 , 0.3-0.7%; and H2 O, 26.0-30.0%. The sea water and salt can exhibit the effect of beautifying the corneous layer of the skin, stimulating the skin function and keeping the skin in healthy conditions by recovering or improving the functions characteristic to the skin. When applied to the aged skin, they can exhibit especially remarkable effect. The compounding ratio to a cosmetic is 0.1-20wt.% in the case of the sea water and 0.02-10wt.%, preferably 0.1-5% in the case of the salt. Further, in the case of a packing agent which is applied for a certain period of time and then removed, a bathing agent which is dissolved in a large amount of hot water for bathing, etc., either of the sea water or the salt is used in the ratio of 10-99wt.%.
PROBLEM TO BE SOLVED: To provide a means for essentially protecting skin from various stimulating substances. SOLUTION: This cosmetic for sensitive skin contains one or more essences selected from Sanguisorba officinalis L. of the family Rosaceae, Artemisia capillaris Thunb., of the family Compositae, Arctium Iappa L. of the family Compositae, Paeonia suffruticosa Andr. of the family Paeoniaceae, Coptis quinquefolia Miq. of the family Ranunculaceae, Lilium longiflorum Thunb. of the family Liliaceae, Saxifraga stolonifera Meerb. of the family Saxifragaceae, Arnica montana L. of the family Compositae and Matricaria chamomilla L. of the Compositae.
Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney transplant recipients, due to factors inherent to concomitant medication and common comorbidities. Recent advances in the field of molecular and clinical nephrology led to a significant improvement in our understanding of glomerular diseases and their more targeted treatment. On the other hand, introduction of novel anticancer drugs tremendously increased patients' survival, at the cost of kidney-related side effects. Our review aims to provide insights into diagnosis and treatment of paraneoplastic glomerular diseases, with a special attention to kidney transplant recipients.
Melatonin (MT) (N-acetyl-5-methoxytryptamine) is an indoleamine recognized primarily for its crucial role in regulating sleep through circadian rhythm modulation in humans and animals. Beyond its association with the pineal gland, it is synthesized in various tissues, functioning as a hormone, tissue factor, autocoid, paracoid, and antioxidant, impacting multiple organ systems, including the gut-brain axis. However, the mechanisms of extra-pineal MT production and its role in microbiota-host interactions remain less understood. This review provides a comprehensive overview of MT, including its production, actions sites, metabolic pathways, and implications for human health. The gastrointestinal tract is highlighted as an additional source of MT, with an examination of its effects on the intestinal microbiota. This review explores whether the microbiota contributes to MT in the intestine, its relationship to food intake, and the implications for human health. Due to its impacts on the intestinal microbiota, MT may be a valuable therapeutic agent for various dysbiosis-associated conditions. Moreover, due to its influence on intestinal MT levels, the microbiota may be a possible therapeutic target for treating health disorders related to circadian rhythm dysregulation.
The invention discloses use of a conjugate of polyethylene glycol and a local anesthetic in non-anesthetic analgesia. A local anesthetic is prepared into a prodrug or a sustained release preparation, wherein a high molecular polymer such as polyethylene glycol in the prodrug is covalently bonded with a local anesthetic, and auxiliary materials with a sustained release effect in the sustained release preparation are non-covalently bonded to the local anesthetic. After administration, there is no anesthesia and analgesic effect before the release of the free local anesthetic. After the free local anesthetic is released, an analgesic effect is achieved. And the prodrug or the sustained-release preparation of the local anesthetic of the present invention releases the drug slowly, and renders the drug concentration kept stable and long-lasting in the effective concentration range of non-narcotic analgesia, and the long-acting non-anesthetic analgesic effect can be achieved while significantly reducing the clinical adverse reactions of local anesthetics and reducing the number of administrations. The effectiveness of the drug is greatly enhanced and the clinical application range of local anesthetics is expanded.
The invention belongs to the technical field of biomedical materials, and particularly relates to a self-repairing electroactive hydrogel and application thereof. The self-repairing electroactive hydrogel provided by the invention is formed by the interaction of an electroactive polymer and a cross-linking agent. The electroactive polymer is a water-soluble polymer, and a main chain or a side chain of the electroactive polymer contains a conductive polymer oligomer. The interaction between the electroactive polymer and the cross-linking agent is one or two of a physical non-covalent bond and a chemical covalent bond. The physical non-covalent bond is hydrogen bond, hydrophobic interaction, electrostatic interaction, pi-pi stacking, host-guest interaction or supermolecular interaction. The chemical covalent bond is one or more of acylhydrazone bond, imine bond, disulfide bond, borate, trithioester and DA reversible covalent bond groups. The self-repairing electroactive hydrogel disclosed by the invention has good electroactive, biocompatibility and self-repairing properties, and has a large application space in the biomedical field, such as the fields of drug delivery, tissue engineering and the like.
Endothelial vasodilatation dysfunction precedes the development of arteriosclerosis. The endothelium plays a pivotal role in the control of the vascular tone by releasing nitric oxide (NO). The amino acid arginine is the sole substrate for the enzyme NO synthase (NOS). Asymmetric dimethylarginine (ADMA) is an endogenous derivative of arginine that inhibits NOS. Thus the arginine/ADMA ratio an important determinant of NO production by NOS. ADMA is an independent risk factor for cardiovascular disease, but elevated levels of ADMA have also been shown to be a strong independent predictor of ICU mortality. The central mechanism by which ADMA may cause deterioration in critically ill patients is by impairing organ blood flow and reducing cardiac function, especially during stress. Accumulation of ADMA could thereby be a causative factor in the development multi organ failure (MOF). Thus inhibition of NO production by ADMA may become especially important when cardiac demand is increased.
BACKGROUND/OBJECTIVE: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are the first-line treatment for exudative age-related macular degeneration (nAMD). Due to the limitations of these standard therapies, targeting alternative mechanisms of action may be helpful for treatment of this very common disease. Here, we investigated an anti-fibroblast growth factor-2 (FGF2) aptamer, umedaptanib pegol, a next generation therapeutic for the treatment of nAMD.
METHODS: Three phase 2 studies were designed. First, a multicentre, randomized, double-masked TOFU study assessed the efficacy of intravitreal injections of umedaptanib pegol monotherapy or in combination with aflibercept, compared to aflibercept monotherapy in 86 subjects with anti-VEGF pretreated nAMD. Second, 22 subjects who had exited the TOFU study received 4 monthly intravitreal injections of umedaptanib pegol (extension, RAMEN study). Third, as an investigator-sponsored trial (TEMPURA study), a single-center, open-label, 4-month study was designed to evaluate the safety and treatment efficacy of umedaptanib pegol in five naïve nAMD patients who had not received any prior anti-VEGF treatment.
RESULTS: The TOFU study demonstrated that umedaptanib pegol alone or in combination with aflibercept did not improve best-corrected visual acuity (BCVA) and central subfield thickness (CST) over aflibercept alone. However, the change in BCVA and CST at primary endpoint was marginal in all the three treatment groups, suggesting that umedaptanib pegol is effective to prevent the disease progression. The RAMEN study confirmed the cessation of disease progression. In the TEMPURA study, naïve nAMD patients showed improvement and no further macular degeneration, with striking improvement of visual acuity and central subfield thickness in some of the patients.
CONCLUSIONS: These results demonstrate, for the first time, clinical proof of concept for aptamer based anti-FGF2 therapy of nAMD.
A method of health monitoring for out-patient is disclosed. The method includes receiving health vital data from the one or more external user devices, organizing received health vital data to create a medical data file representative of medical history of a user. The method includes analysing the processed medical data file to generate one or more patterns corresponding to the health vital data and generating one or more recommendations provided by a healthcare provider based on the one or more patterns. The method includes generating alerts to health care practitioner, kith & kin, health care practitioner based on out-patient's permissions. The method includes generating a benchmark result based on the one or more patterns and the one or more recommendations by the healthcare provider. The method includes recommending the benchmark result of the user to one or more patients comprising same race, age, gender and weight that of the user.
FIELD: medicine, pharmacology. SUBSTANCE: invention proposes cyclohexapeptide for treatment as drug of the following structural formula: cyclo-lysyl-histidyl-glycyl-lysyl-histidyl-glycine. Drug has glycine as stabilizing agent (vehicle) additionally. Drug shows high effectiveness of effect with respect to stimulation of humoral immunity, immune response potency and molecules of intercellular interaction in therapy of immunodeficiency states. EFFECT: enhanced effectiveness of agent. 3 cl, 2 tbl, 4 ex
IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every three weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). Patients will not receive Varlilumab.
FIELD: cosmetics. SUBSTANCE: agent comprises acetone, vegetable raw CO 2 -extracts complex and conditioning substances. Agent comprises either oxyethylated hydrogenated castor oil and/or polyethylene glycol, and/or propylene glycol, and/or copolymer of polyethylene glycol and polypropylene glycol as conditioning substances designated for normalization of nail state and for solubilization of CO 2 -extracts of vegetable raw also. Agent for removal of nail enamel washes out enamel from nail plate and owing to the presence of vegetable raw CO 2 -extracts and conditioning substances exhibits protective, hydrating, disinfecting, nutrient, vitaminizing, tonic and aromatic effect. EFFECT: enhanced effectiveness and valuable properties of agent. 3 cl, 1 tbl, 4 ex
Participants received intravenous infusions of QL1706 5mg/kg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 mg/mL/min followed by etoposide 100 mg/m\^2 on Day 1 of every 21-day cycle for 4-6 cycles. On Days 2 and 3 of every 21-day cycle, etoposide 100 mg/m\^2 was administered alone for 4-6 cycles. Thereafter, participants received maintenance QL1706 5mg/kg on Day 1 of every 21-day cycle until progressive disease, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.